PROF. GIRISH SHAH, the recipient of “Outstanding Achievement in Carcinoid/ Neuroendocrine Tumor Research” in 2006 from the Carcinoid Cancer Foundation, Inc. of USA, is a Professor at the Faculty of Medicine at Laval University in Quebec City. He has been chief of the Laboratory for Skin Cancer Research at the CHU de Quebec (CHUL) Hospital Research Centre of Laval University since 1997. Prof. Shah’s research is focused on carcinoid neuroendocrine tumors and solar ultraviolet radiation-induced skin cancers with specific emphasis on DNA damage, DNA repair and cell death processes, all of which can influence either the development of these cancers or their resistance to therapy. Dr. Shah has authored 55 peer-reviewed articles, which have been cited more than 2,387 times in literature. In addition, he has authored 4 book chapters and 119 presentations at the meetings. Dr. Shah’s team, in collaboration with two carcinoid clinicians in Canada and USA, had earlier reported that nearly ¼ of the carcinoid neuroendocrine tumor patients suffer from subclinical niacin (vitamin B3) deficiency, an incidence that is much higher than pellagra, the clinical niacin deficiency syndrome reported in these patients. His recent work has identified how this biochemical anomaly can be exploited to improve efficiency of chemotherapy of carcinoid NET cancers. He is currently also the President of the Scientific & Medical Advisory Board of CNETS Canada.

Miranda works as a health policy analyst for the Canadian Cancer Society where she is responsible for synthesizing the evidence used to raise awareness of issues affecting people with cancer and affect policy change. Her policy areas of expertise include drug access (pharmacare, drug shortages, take-home-cancer-drugs and biosimilars), health human resources and sickness benefits and leave. In the past, she worked as a medical assistant and patient advocate in the oncology department of the Jewish General Hospital, where her work helped her to recognize the important role of age and cancer type in cancer care, and to identify the unique challenges of providing optimal care for those living with a rare disease and those diagnosed with cancer in young adulthood. Miranda has been a fierce advocate for people with cancer since her first day of work at the hospital, and her commitment to making a difference in the lives of people living with neuroendocrine cancer is fueled by the loss of her family member Douglas (2012) and her beloved partner Daniel (2019) to the disease. Miranda strongly believes in CNETS ability to improve the lives of people living with NET cancer through their awareness, advocacy, research and patient support.

After being diagnosed with metastatic Neuroendocrine cancer in 2023, Angela discovered the support, community and unwavering dedication of CNETS to NET cancer patients and their families. Having always volunteered with community organizations and initiatives throughout her life, she became involved in patient advocacy and NET Cancer awareness with CNETS in 2024 drawing on her background in Administration in Education. Angela is enthusiastic about the opportunity to have an impact on the evolution of better diagnostic timing, diagnostic techniques, treatments and outcomes for NET patients as CNETS continues to work with researchers and practitioners in Canada and internationally.
She lives in Ottawa with her husband where they enjoy outdoor sporting pursuits, indoor creative making and frequent visits from their local three (launched) adult children.